Inflazome is a biotech company that develops new drugs to block harmful inflammation. The company is creating potent and selective small-molecule inhibitors of the NLRP3 inflammasome, to stop the cycle of chronic inflammation that drives Alzheimer’s (lat. morbus Alzheimerianus) and Parkinson’s diseases (lat. Parkinson scriptor morbus) as well as inflammatory bowel disease, gout, osteoarthritis, liver, kidney and cardiovascular diseases. Inflazome has already secured further investment of $63 million. Launched in 2016, Inflazome was founded on research from The University of Queensland and Trinity College Dublin in Ireland. The Series B financing will be used to advance the company's small-molecule inhibitors of the NLRP3 inflammasome in to multiple clinical trials in 2019.

Inflazome was founded on intellectual property licensed by UQ's commercialisation company UniQuest, based on work by researchers from UQ's Institute for Molecular Bioscience (IMB) and Trinity College Dublin, including IMB's Professor Matt Cooper, who is also the company's CEO.

The spinoff successfully completed a Series B financing round of €40 million ($46 million), which was led by Forbion, with Longitude Capital and founding investors, Novartis Venture Fund and Fountain Healthcare Partners, also participating.

Clinical and scientific data indicates that the NLRP3 inflammasome, a compelling biological target that regulates our innate immune response, is overactive in a broad range of serious medical conditions driven by harmful inflammation. These include neurological disorders such as Alzheimer's and Parkinson's as well as inflammatory bowel disease, gout, osteoarthritis, liver, kidney and cardiovascular diseases; conditions often inadequately treated by current therapies.

Inflazome is developing potent and selective small-molecule inhibitors of the NLRP3 inflammasome, to stop the cycle of chronic inflammation that drives such diseases. The Series B proceeds will be used to advance the Company's first-in-class NLRP3 inflammasome inhibitors into multiple clinical trials in 2019, with next-generation compounds following thereafter.

Professor Cooper, CEO, said that the potential of NLRP3 inhibitors as a drug target was incredibly exciting. The company's team looks forward to generating robust human proof of concept data with this financing, and making further progress towards developing a treatment to help millions of patients who are suffering from inflammatory diseases.

In addition, the IMB research team included Dr Rebecca Coll and Professor Avril Robertson in collaboration with Associate Professor Trent Woodruff from UQ’s Faculty of Medicine, and Professor Luke O’Neill at Trinity College Dublin.